{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:28:43Z","timestamp":1789392523723,"version":"build-2803163510"},"reference-count":119,"publisher":"Rambam Health Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10386","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T13:14:18Z","timestamp":1584018858000},"page":"e0003","source":"Crossref","is-referenced-by-count":41,"title":["Medical Cannabis in Children"],"prefix":"10.5041","volume":"11","author":[{"given":"Adi","family":"Aran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalit","family":"Cayam-Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/226701a0","article-title":"Marijuana intoxication common experiences","volume":"226","author":"Tart","year":"1970","unstructured":"1. Tart CT. Marijuana intoxication common experiences. Nature 1970;226:701-4.","journal-title":"Nature"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/00952997709002763","article-title":"The effect of marijuana on small group process","volume":"4","author":"Salzman","year":"1977","unstructured":"2. Salzman C, Kochansky GE, Van Der Kolk BA, Shader RI. The effect of marijuana on small group process. Am J Drug Alcohol Abuse 1977;4:251-5.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1176\/ajp.133.9.1029","article-title":"Marijuana and hostility in a small-group setting","volume":"133","author":"Salzman","year":"1976","unstructured":"3. Salzman C, Van Der Kolk BA, Shader RI. Marijuana and hostility in a small-group setting. Am J Psychiatry 1976;133:1029-33.","journal-title":"Am J Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3389\/fpls.2018.01969","article-title":"The case for the entourage effect and conventional breeding of clinical cannabis: no \"strain,\" no gain","volume":"9","author":"Russo","year":"2018","unstructured":"4. Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no \"strain,\" no gain. Front Plant Sci 2018;9:1969.","journal-title":"Front Plant Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","unstructured":"5. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.","journal-title":"J Am Chem Soc"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"Hashish-I: The structure of cannabidiol","volume":"12","author":"Mechoulam","year":"1963","unstructured":"6. Mechoulam R, Shvo Y. Hashish-I: The structure of cannabidiol. Tetrahedron 1963;12:2073-8.","journal-title":"Tetrahedron"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","unstructured":"7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3389\/fphar.2018.01496","article-title":"Some prospective alternatives for treating pain: the endocannabinoid system and its putative receptors GPR18 and GPR55","volume":"9","author":"Guerrero-Alba","year":"2018","unstructured":"8. Guerrero-Alba R, Barrag\u00e1n-Iglesias P, Gonz\u00e1lez-Hern\u00e1ndez A, et al. Some prospective alternatives for treating pain: the endocannabinoid system and its putative receptors GPR18 and GPR55. Front Pharmacol 2018;9:1496.","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41386-018-0282-7","article-title":"\u0394-9-Tetrahydrocannabinol and cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors","volume":"44","author":"Szkudlarek","year":"2019","unstructured":"9. Szkudlarek HJ, Desai SJ, Renard J, et al. \u0394-9-Tetrahydrocannabinol and cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors. Neuropsychopharmacology 2019;44:817-25.","journal-title":"Neuropsychopharmacology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","unstructured":"10. Campos AC, Foga\u00e7a MV, Scarante FF, et al. Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol 2017;8:269.","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","unstructured":"11. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 2018;175:225-31.","journal-title":"Am J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","unstructured":"12. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802.","journal-title":"Epilepsia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","unstructured":"13. Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 2014;5:1131-41.","journal-title":"ACS Chem Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0014-2999(98)00392-6","article-title":"An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity","volume":"353","author":"Ben-Shabat","year":"1998","unstructured":"14. Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998;353:23-31.","journal-title":"Eur J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","unstructured":"15. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163:1344-64.","journal-title":"Br J Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/ana.24402","article-title":"The entourage effect of the phytocannabinoids","volume":"77","author":"Sanchez-Ramos","year":"2015","unstructured":"16. Sanchez-Ramos J. The entourage effect of the phytocannabinoids. Ann Neurol 2015;77:1083.","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bcp.2018.06.025","article-title":"Appraising the \"entourage effect\": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer","volume":"157","author":"Blasco-Benito","year":"2018","unstructured":"17. Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, et al. Appraising the \"entourage effect\": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol 2018;157:285-93.","journal-title":"Biochem Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Ferber SG, Namdar D, Hen-Shoval D, et al. The \"entourage effect\": Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol 2020;18(2).","DOI":"10.2174\/1570159X17666190903103923"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Namdar D, Voet H, Ajjampura V, et al. Terpenoids and phytocannabinoids co-produced in Cannabis sativa strains show specific interaction for cell cytotoxic activity. Molecules 2019;24:pii:E3031.","DOI":"10.3390\/molecules24173031"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/can.2019.0016","article-title":"Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of \u03949-THC at human CB1 and CB2 receptors","volume":"4","author":"Santiago","year":"2019","unstructured":"20. Santiago M, Sachdev S, Arnold JC, McGregor IS, Connor M. Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of \u03949-THC at human CB1 and CB2 receptors. Cannabis Cannabinoid Res 2019;4:165-76.","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/07853890.2016.1145794","article-title":"Cannabinoids: medical implications","volume":"48","author":"RJ","year":"2016","unstructured":"21. Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med 2016;48:128-41.","journal-title":"Ann Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jaac.2016.12.014","article-title":"Evidence for the risks and consequences of adolescent cannabis exposure","volume":"56","author":"Levine","year":"2017","unstructured":"22. Levine A, Clemenza K, Rynn M, Lieberman J. Evidence for the risks and consequences of adolescent cannabis exposure. J Am Acad Child Adolesc Psychiatry 2017;56:214-25.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/ejp.1377","article-title":"Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders","volume":"23","author":"Krebs","year":"2019","unstructured":"23. Krebs MO, Kebir O, Jay TM. Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. Eur J Pain 2019;23:1225-33.","journal-title":"Eur J Pain"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis","volume":"35","author":"Morgan","year":"2010","unstructured":"24. Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010; 35:1879-85.","journal-title":"Neuropsychopharmacology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S0033291711001322","article-title":"Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being","volume":"42","author":"Morgan","year":"2012","unstructured":"25. Morgan CJ, Gardener C, Schafer G, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 2012;42:391-400.","journal-title":"Psychol Med"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Zlebnik NE, Cheer JF. Beyond the CB1 receptor: is cannabidiol the answer for disorders of motivation? Annu Rev Neurosci 2016;39:1-17.","DOI":"10.1146\/annurev-neuro-070815-014038"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd","year":"2015","unstructured":"27. Hurd YL, Yoon M, Manini AF, et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 2015;12:807-15.","journal-title":"Neurotherapeutics"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","article-title":"Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study","volume":"197","author":"Morgan","year":"2010","unstructured":"28. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010;197:285-90.","journal-title":"Br J Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Lorenzetti V, Solowij N, Y\u00fccel M. The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry 2016;79:e17-31.","DOI":"10.1016\/j.biopsych.2015.11.013"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"TA","year":"2015","unstructured":"30. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 2015;162:153-61.","journal-title":"Schizophr Res"},{"key":"ref30","unstructured":"31. Silva TB, Balbino CQ, Weiber AF. The relationship between cannabidiol and psychosis: a review. Ann Clin Psychiatry 2015;27:134-41."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0020764018801690","article-title":"Cannabis consumption and psychosis or schizophrenia development","volume":"64","author":"Ortiz-Medina","year":"2018","unstructured":"32. Ortiz-Medina MB, Perea M, Torales J, et al. Cannabis consumption and psychosis or schizophrenia development. Int J Soc Psychiatry 2018;64:690-704.","journal-title":"Int J Soc Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","unstructured":"33. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014;370:2219-27.","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/jamapsychiatry.2015.1131","article-title":"Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence","volume":"72","author":"French","year":"2015","unstructured":"34. French L, Gray C, Leonard G, et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry 2015; 72:1002-11.","journal-title":"JAMA Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","unstructured":"35. Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results. Epilepsy Res 2019;154:13-20.","journal-title":"Epilepsy Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results","volume":"59","author":"Szaflarski","year":"2018","unstructured":"36. Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia 2018;59: 1540-8.","journal-title":"Epilepsia"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"106635","DOI":"10.1016\/j.yebeh.2019.106635","article-title":"Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis","volume":"102","author":"de Carvalho Reis","year":"2019","unstructured":"37. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis. Epilepsy Behav 2019;102: 106635.","journal-title":"Epilepsy Behav"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neuropharm.2019.01.002","article-title":"Preclinical safety and efficacy of cannabidivarin for early life seizures","volume":"148","author":"Huizenga","year":"2019","unstructured":"38. Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology 2019;148: 189-98.","journal-title":"Neuropharmacology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2019.01131","article-title":"Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats","volume":"10","author":"Cepri\u00e1n","year":"2019","unstructured":"39. Cepri\u00e1n M, Vargas C, Garcia-Toscano L, et al. Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats. Front Pharmacol 2019;10:1131.","journal-title":"Front Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Scheyer AF, Borsoi M, Wager-Miller J, et al. Cannabinoid exposure via lactation in rats disrupts perinatal programming of the gamma-aminobutyric acid trajectory and select early-life behaviors. Biol Psychiatry 2019;in press.","DOI":"10.1016\/j.biopsych.2019.08.023"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.tins.2019.08.010","article-title":"Consequences of perinatal cannabis exposure","volume":"42","author":"Scheyer","year":"2019","unstructured":"41. Scheyer AF, Melis M, Trezza V, Manzoni OJJ. Consequences of perinatal cannabis exposure. Trends Neurosci 2019;42:871-84.","journal-title":"Trends Neurosci"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Thorpe HHA, Hamidullah S, Jenkins BW, Khokhar JY. Adolescent neurodevelopment and substance use: receptor expression and behavioral consequences. Pharmacol Ther 2019:107431.","DOI":"10.1016\/j.pharmthera.2019.107431"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40263-018-0550-4","article-title":"Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system","volume":"32","author":"Schonhofen","year":"2018","unstructured":"43. Schonhofen P, Bristot IJ, Crippa JA, et al. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs 2018;32:697-712.","journal-title":"CNS Drugs"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","unstructured":"44. Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J Autism Dev Disord 2019;49:1284-8.","journal-title":"J Autism Dev Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel","year":"2019","unstructured":"45. Barchel D, Stolar O, De-Haan T, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 2019;9:1521.","journal-title":"Front Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider","year":"2019","unstructured":"46. Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 2019;9:200.","journal-title":"Sci Rep"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use","volume":"10","author":"Fleury-Teixeira","year":"2019","unstructured":"47. Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, Brasil-Neto JP, Malcher-Lopes R. Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use. Front Neurol 2019;10:1145.","journal-title":"Front Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: a meta-analytic approach","volume":"51","author":"Ngugi","year":"2010","unstructured":"48. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51:883-90.","journal-title":"Epilepsia"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","unstructured":"49. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol 2018;75:279-86.","journal-title":"JAMA Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.yebeh.2016.09.040","article-title":"Cannabis and epilepsy: an ancient treatment returns to the fore","volume":"70","author":"Russo","year":"2017","unstructured":"50. Russo EB. Cannabis and epilepsy: an ancient treatment returns to the fore. Epilepsy Behav 2017;70: 292-7.","journal-title":"Epilepsy Behav"},{"key":"ref50","unstructured":"51. U.S. Food and Drug Administration. FDA news release: FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Available at: www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm611046.htm (accessed January 9, 2020)."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","unstructured":"52. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270-8.","journal-title":"Lancet Neurol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","unstructured":"53. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20.","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","unstructured":"54. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:1888-97.","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jamapediatrics.2018.4208","article-title":"Prevalence and treatment patterns of autism spectrum disorder in the United States, 2016","volume":"173","author":"Xu","year":"2019","unstructured":"55. Xu G, Strathearn L, Liu B, et al. Prevalence and treatment patterns of autism spectrum disorder in the United States, 2016. JAMA Pediatr 2019;173:153-9.","journal-title":"JAMA Pediatr"},{"key":"ref55","unstructured":"56. American Psychiatric Association. Autism Spectrum Disorder, 299.00 (F84.0). In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, Virginia: American Psychiatric Publishing; 2013:50-5."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-2788.2008.01065.x","article-title":"Prevalence and risk factors of maladaptive behaviour in young children with autistic disorder","volume":"52","author":"Hartley","year":"2008","unstructured":"57. Hartley SL, Sikora DM, McCoy R. Prevalence and risk factors of maladaptive behaviour in young children with autistic disorder. J Intellect Disabil Res 2008; 52:819-29.","journal-title":"J Intellect Disabil Res"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3109\/15622970902789130","article-title":"High rates of psychiatric co-morbidity in individuals with Asperger's disorder","volume":"11","author":"NM","year":"2010","unstructured":"58. Mukaddes NM, Fateh R. High rates of psychiatric co-morbidity in individuals with Asperger's disorder. World J Biol Psychiatry 2010;11:486-92.","journal-title":"World J Biol Psychiatry"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s10803-010-1118-4","article-title":"Aggression in children and adolescents with ASD: prevalence and risk factors","volume":"41","author":"SM","year":"2011","unstructured":"59. Kanne SM, Mazurek MO. Aggression in children and adolescents with ASD: prevalence and risk factors. J Autism Dev Disord 2011;41:926-37.","journal-title":"J Autism Dev Disord"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/A:1005523232106","article-title":"Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder","volume":"30","author":"Green","year":"2000","unstructured":"60. Green J, Gilchrist A, Burton D, Cox A. Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. J Autism Dev Disord 2000;30:279-93.","journal-title":"J Autism Dev Disord"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:JADD.0000022606.97580.19","article-title":"Comparing rates of psychiatric and behavior disorders in adolescents and young adults with severe intellectual disability with and without autism","volume":"34","author":"Bradley","year":"2004","unstructured":"61. Bradley EA, Summers JA, Wood HL, Bryson SE. Comparing rates of psychiatric and behavior disorders in adolescents and young adults with severe intellectual disability with and without autism. J Autism Dev Disord 2004;34:151-61.","journal-title":"J Autism Dev Disord"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1023\/B:JADD.0000037415.21458.93","article-title":"Psychiatric symptoms in preschool children with PDD and clinic and comparison samples","volume":"34","author":"Gadow","year":"2004","unstructured":"62. Gadow KD, DeVincent CJ, Pomeroy J, Azizian A. Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. J Autism Dev Disord 2004;34:379-93.","journal-title":"J Autism Dev Disord"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1365-2788.2005.00699.x","article-title":"Preschool children with intellectual disability: syndrome specificity, behaviour problems, and maternal well-being","volume":"49","author":"Eisenhower","year":"2005","unstructured":"63. Eisenhower AS, Baker BL, Blacher J. Preschool children with intellectual disability: syndrome specificity, behaviour problems, and maternal well-being. J Intellect Disabil Res 2005;49:657-71.","journal-title":"J Intellect Disabil Res"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10803-006-0125-y","article-title":"Psychopathology in children and adolescents with autism compared to young people with intellectual disability","volume":"36","author":"Brereton","year":"2006","unstructured":"64. Brereton AV, Tonge BJ, Einfeld SL. Psychopathology in children and adolescents with autism compared to young people with intellectual disability. J Autism Dev Disord 2006;36:863-70.","journal-title":"J Autism Dev Disord"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ridd.2005.07.001","article-title":"Patterns of emotional and behavioural disturbance associated with autistic traits in young people with severe intellectual disabilities and challenging behaviours","volume":"27","author":"Hill","year":"2006","unstructured":"65. Hill J, Furniss F. Patterns of emotional and behavioural disturbance associated with autistic traits in young people with severe intellectual disabilities and challenging behaviours. Res Dev Disabil 2006;27: 517-28.","journal-title":"Res Dev Disabil"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaac.2011.11.010","article-title":"Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems","volume":"51","author":"Scahill","year":"2012","unstructured":"66. Scahill L, McDougle CJ, Aman MG, et al. Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. J Am Acad Child Adolesc Psychiatry 2012;51:136-46.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10803-012-1622-9","article-title":"Emotional and behavioural problems in children with autism spectrum disorder","volume":"43","author":"Maskey","year":"2013","unstructured":"67. Maskey M, Warnell F, Parr JR, Le Couteur A, McConachie H. Emotional and behavioural problems in children with autism spectrum disorder. J Autism Dev Disord 2013;43:851-9.","journal-title":"J Autism Dev Disord"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10803-005-0007-8","article-title":"Systems analysis of stress and positive perceptions in mothers and fathers of pre-school children with autism","volume":"35","author":"Hastings","year":"2005","unstructured":"68. Hastings RP, Kovshoff H, Ward NJ, degli Espinosa F, Brown T, Remington B. Systems analysis of stress and positive perceptions in mothers and fathers of pre-school children with autism. J Autism Dev Disord 2005;35:635-44.","journal-title":"J Autism Dev Disord"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2788.2005.00732.x","article-title":"The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders","volume":"50","author":"Lecavalier","year":"2006","unstructured":"69. Lecavalier L, Leone S, Wiltz J. The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. J Intellect Disabil Res 2006;50:172-83.","journal-title":"J Intellect Disabil Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10803-012-1604-y","article-title":"The impact of parenting stress: a meta-analysis of studies comparing the experience of parenting stress in parents of children with and without autism spectrum disorder","volume":"43","author":"SA","year":"2013","unstructured":"70. Hayes SA, Watson SL. The impact of parenting stress: a meta-analysis of studies comparing the experience of parenting stress in parents of children with and without autism spectrum disorder. J Autism Dev Disord 2013;43:629-42.","journal-title":"J Autism Dev Disord"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1023\/A:1020593922901","article-title":"Problem behavior interventions for young children with autism: a research synthesis","volume":"32","author":"Horner","year":"2002","unstructured":"71. Horner RH, Carr EG, Strain PS, Todd AW, Reed HK. Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 2002;32:423-46.","journal-title":"J Autism Dev Disord"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1753-2000-3-7","article-title":"The clinical effectiveness of different parenting programmes for children with conduct problems: a systematic review of randomised controlled trials","volume":"3","author":"Dretzke","year":"2009","unstructured":"72. Dretzke J, Davenport C, Frew E, et al. The clinical effectiveness of different parenting programmes for children with conduct problems: a systematic review of randomised controlled trials. Child Adolesc Psychiatry Ment Health 2009;3:7.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"73. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;10:CD009260.","DOI":"10.1002\/14651858.CD009260.pub2"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"74. Oono IP, Honey EJ, McConachie H. Parent-mediated early intervention for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013;4:CD009774.","DOI":"10.1002\/14651858.CD003496.pub2"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1001\/jama.2015.3150","article-title":"Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial","volume":"313","author":"Bearss","year":"2015","unstructured":"75. Bearss K, Johnson C, Smith T, et al. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. JAMA 2015;313:1524-33.","journal-title":"JAMA"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial","volume":"48","author":"Aman","year":"2009","unstructured":"76. Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009;48:1143-54.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2217\/npy.13.14","article-title":"Toward an exportable parent training program for disruptive behaviors in autism spectrum disorders","volume":"3","author":"Bearss","year":"2013","unstructured":"77. Bearss K, Lecavalier L, Minshawi N, et al. Toward an exportable parent training program for disruptive behaviors in autism spectrum disorders. Neuropsychiatry (London) 2013;3:169-80.","journal-title":"Neuropsychiatry (London)"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","unstructured":"78. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-21.","journal-title":"N Engl J Med"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"79. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-41.","DOI":"10.1542\/peds.2003-0264-F"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"80. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005;162: 1361-9.","DOI":"10.1176\/appi.ajp.162.7.1361"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/01.chi.0000196423.80717.32","article-title":"Risperidone and adaptive behavior in children with autism","volume":"45","author":"Williams","year":"2006","unstructured":"81. Williams SK, Scahill L, Vitiello B, et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry 2006;45:431-9.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"82. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev 2017;(8):CD008559.","DOI":"10.1002\/14651858.CD008559.pub3"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1517\/14656566.2016.1154536","article-title":"Psychopharmacological interventions in autism spectrum disorder","volume":"17","author":"Accordino","year":"2016","unstructured":"83. Accordino RE, Kidd C, Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Expert Opin Pharmacother 2016;17:937-52.","journal-title":"Expert Opin Pharmacother"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eurpsy.2015.11.004","article-title":"Initial severity and efficacy of risperidone in autism: results from the RUPP trial","volume":"32","author":"Levine","year":"2016","unstructured":"84. Levine SZ, Kodesh A, Goldberg Y, et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. Eur Psychiatry 2016;32:16-20.","journal-title":"Eur Psychiatry"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WNF.0000000000000096","article-title":"Mood stabilizers in children and adolescents with autism spectrum disorders","volume":"38","author":"Canitano","year":"2015","unstructured":"85. Canitano R. Mood stabilizers in children and adolescents with autism spectrum disorders. Clin Neuropharmacol 2015;38:177-82.","journal-title":"Clin Neuropharmacol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/YCO.0000000000000132","article-title":"An update on pharmacotherapy for autism spectrum disorder in children and adolescents","volume":"28","author":"Ji","year":"2015","unstructured":"86. Ji N, Findling RL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 2015;28:91-101.","journal-title":"Curr Opin Psychiatry"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1362361314524641","article-title":"Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study","volume":"19","author":"Adler","year":"2015","unstructured":"87. Adler BA, Wink LK, Early M, et al. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study. Autism 2015;19:102-6.","journal-title":"Autism"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s10803-013-2028-z","article-title":"Determinants of stress in parents of children with autism spectrum disorders","volume":"44","author":"Rivard","year":"2014","unstructured":"88. Rivard M, Terroux A, Parent-Boursier C, Mercier C. Determinants of stress in parents of children with autism spectrum disorders. J Autism Dev Disord 2014;44:1609-20.","journal-title":"J Autism Dev Disord"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00431-015-2531-7","article-title":"Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe","volume":"174","author":"Salomone","year":"2015","unstructured":"89. Salomone E, Charman T, McConachie H, Warreyn P; Working Group 4, COST Action 'Enhancing the Scientific Study of Early Autism'. Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe. Eur J Pediatr 2015;174:1277-85.","journal-title":"Eur J Pediatr"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.rasd.2015.05.002","article-title":"Prevalence and predictors of complementary and alternative medicine use in a large insured sample of children with autism spectrum disorders","volume":"17","author":"Owen-Smith","year":"2015","unstructured":"90. Owen-Smith AA, Bent S, Lynch FL, et al. Prevalence and predictors of complementary and alternative medicine use in a large insured sample of children with autism spectrum disorders. Res Autism Spectr Disord 2015;17:40-51.","journal-title":"Res Autism Spectr Disord"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/1098-2779(2000)6:4<300::AID-MRDD9>3.0.CO;2-R","article-title":"Epilepsy and epileptiform EEG: association with autism and language disorders","volume":"6","author":"Ballaban-Gil K","year":"2000","unstructured":"91. Ballaban-Gil K, Tuchman R. Epilepsy and epileptiform EEG: association with autism and language disorders. Ment Retard Dev Disabil Rev 2000;6: 300-8.","journal-title":"Ment Retard Dev Disabil Rev"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s10072-017-2974-x","article-title":"Autism, epilepsy, and synaptopathies: a not rare association","volume":"38","author":"Keller","year":"2017","unstructured":"92. Keller R, Basta R, Salerno L, Elia M. Autism, epilepsy, and synaptopathies: a not rare association. Neurol Sci 2017;38:1353-61.","journal-title":"Neurol Sci"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"93. Seeley WW, Zhou J, Kim EJ. Frontotemporal dementia: what can the behavioral variant teach us about human brain organization? Neuroscientist 2012;18: 373-85.","DOI":"10.1177\/1073858411410354"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","article-title":"Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain","volume":"77","author":"Glass","year":"1997","unstructured":"94. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77:299-318.","journal-title":"Neuroscience"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neuropharm.2007.07.005","article-title":"Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors","volume":"54","author":"Moreira","year":"2008","unstructured":"95. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008;54:141-50.","journal-title":"Neuropharmacology"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-010-2051-0","article-title":"Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice","volume":"214","author":"Cassano","year":"2011","unstructured":"96. Cassano T, Gaetani S, Macheda T, et al. Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. Psychopharmacology 2011;214:465-76.","journal-title":"Psychopharmacology"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"14899","DOI":"10.1523\/JNEUROSCI.0114-12.2012","article-title":"Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats","volume":"32","author":"Trezza","year":"2012","unstructured":"97. Trezza V, Damsteegt R, Manduca A, et al. Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. J Neurosci 2012;32:14899-908.","journal-title":"J Neurosci"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.tips.2010.06.008","article-title":"The pleasures of play: pharmacological insights into social reward mechanisms","volume":"31","author":"Trezza","year":"2010","unstructured":"98. Trezza V, Baarendse PJ, Vanderschuren LJ. The pleasures of play: pharmacological insights into social reward mechanisms. Trends Pharmacol Sci 2010;31: 463-9.","journal-title":"Trends Pharmacol Sci"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1017\/S146114570999023X","article-title":"Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats","volume":"13","author":"Seillier","year":"2010","unstructured":"99. Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Ing J Neuropsychopharmacol 2010;13:373-86.","journal-title":"Ing J Neuropsychopharmacol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/npp.2013.81","article-title":"Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia","volume":"38","author":"Seillier","year":"2013","unstructured":"100. Seillier A, Martinez AA, Giuffrida A. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia. Neuropsychopharmacology 2013;38:1816-24.","journal-title":"Neuropsychopharmacology"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/hup.2374","article-title":"Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report","volume":"29","author":"Bergamaschi","year":"2014","unstructured":"101. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Hum Psychopharmacol 2014;29:94-9.","journal-title":"Hum Psychopharmacol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/mp.2012.72","article-title":"Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity","volume":"18","author":"Gunduz-Cinar","year":"2013","unstructured":"102. Gunduz-Cinar O, MacPherson KP, Cinar R, et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013;18:813-23.","journal-title":"Mol Psychiatry"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1523\/JNEUROSCI.5603-07.2008","article-title":"Cannabinoid modulation of amygdala reactivity to social signals of threat in humans","volume":"28","author":"Phan","year":"2008","unstructured":"103. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008;28:2313-19.","journal-title":"J Neurosci"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"14084","DOI":"10.1073\/pnas.1509795112","article-title":"Endocannabinoid signaling mediates oxytocin-driven social reward","volume":"112","author":"Wei","year":"2015","unstructured":"104. Wei D, Lee D, Cox CD, et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S A 2015;112:14084-9.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"105. Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci 2017;18:pii: E1916.","DOI":"10.3390\/ijms18091916"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/mp.2017.221","article-title":"Treating a novel plasticity defect rescues episodic memory in Fragile X model mice","volume":"23","author":"Wang","year":"2018","unstructured":"106. Wang W, Cox BM, Jia Y, et al. Treating a novel plasticity defect rescues episodic memory in Fragile X model mice. Mol Psychiatry 2018;23:1798-806.","journal-title":"Mol Psychiatry"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fncel.2018.00234","article-title":"Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3R451C mouse model of autism","volume":"12","author":"Hosie","year":"2018","unstructured":"107. Hosie S, Malone DT, Liu S, et al. Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3R451C mouse model of autism. Front Cell Neurosci 2018;12:234.","journal-title":"Front Cell Neurosci"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1111\/bph.14435","article-title":"Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling","volume":"175","author":"Melancia","year":"2018","unstructured":"108. Melancia F, Schiavi S, Servadio M, et al. Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling. Br J Pharmacol 2018;175:3699-712.","journal-title":"Br J Pharmacol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","article-title":"Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder","volume":"44","author":"Pretzsch","year":"2019","unstructured":"109. Pretzsch CM, Freyberg J, Voinescu B, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology 2019;44:1398-405.","journal-title":"Neuropsychopharmacology"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","unstructured":"110. Karhson DS, Krasinska KM, Dallaire JA, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism 2018;9: 18.","journal-title":"Mol Autism"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","unstructured":"111. Aran A, Eylon M, Harel M, et al. Lower circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism 2019;10:2.","journal-title":"Mol Autism"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.neuron.2013.04.030","article-title":"Evidence for a common endocannabinoid-related pathomechanism in autism spectrum disorders","volume":"78","author":"DD","year":"2013","unstructured":"112. Krueger DD, Brose N. Evidence for a common endocannabinoid-related pathomechanism in autism spectrum disorders. Neuron 2013;78:408-10.","journal-title":"Neuron"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","unstructured":"113. Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs 2018;78:1791-804.","journal-title":"Drugs"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/aur.1798","article-title":"Placebo-like response in absence of treatment in children with autism","volume":"10","author":"Jones","year":"2017","unstructured":"114. Jones RM, Carberry C, Hamo A, Lord C. Placebo-like response in absence of treatment in children with autism. Autism Res 2017;10:1567-72.","journal-title":"Autism Res"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","article-title":"Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users","volume":"25","author":"Hindocha","year":"2015","unstructured":"115. Hindocha C, Freeman TP, Schafer G, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 2015; 25:325-34.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0883073818773028","article-title":"Medical cannabis for pediatric moderate to severe complex motor disorders","volume":"33","author":"Libzon","year":"2018","unstructured":"116. Libzon S, Schleider LB, Saban N, et al. Medical cannabis for pediatric moderate to severe complex motor disorders. J Child Neurol 2018;33:565-71.","journal-title":"J Child Neurol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ejpn.2016.07.021","article-title":"Effective treatment of spasticity using dronabinol in pediatric pal-liative care","volume":"20","author":"Kuhlen","year":"2016","unstructured":"117. Kuhlen M, Hoell JI, Gagnon G, et al. Effective treatment of spasticity using dronabinol in pediatric pal-liative care. Eur J Paediatr Neurol 2016;20:898-903.","journal-title":"Eur J Paediatr Neurol"},{"key":"ref117","unstructured":"118. Wilson JL, Gregory A, Wakeman K, et al. Cannabis use in children with pantothenate kinase-associated neurodegeneration. J Child Neurol 2019;11; 883073819890516. [Epub ahead of print]"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"119. Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics 2017;140:pii:e20171818.","DOI":"10.1542\/peds.2017-1818"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/1010\/1\/PublishFiles\/1026Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T10:18:25Z","timestamp":1738750705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/44\/articles\/1026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,30]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10386","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}